Does HBOC-201 (hemopure) affect platelet function in orthopedic surgery: A single-site analysis from a multicenter study

Jonathan S. Jahr, Hong Liu, Olga K. Albert, Amy Gull, Mojgan Moallempour, Jennifer Lim, Robert Gosselin

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

HBOC-201, Hemoglobin glutamer-250 (bovine), (Biopure Corp., Cambridge, MA) has been studied in an international, multicenter, pivotal Phase III trial. A subset analysis of use of blood products indicated that the HBOC-201 group required no more than the packed red blood cell (PRBC) group and was limited to less than 6% in both treatment groups. In a subset analysis from one site, platelet function using PFA-100 was assessed before and after transfusion, and compared those receiving HBOC-201 versus PRBC. After initial IRB approval, patient consent for the Phase III trial and blood draws for PFA-100, an additional IRB exemption for retrospective chart review was obtained. cEPI and cADP means were compared at seven time periods: true baseline(before starting surgery and anesthesia), before transfusion, after transfusion, 1 day, 2 days, 3 to 9 days and 21 or more days after transfusion. Twenty-seven (HBOC: n = 12, PRBC: n = 15) subjects were studied. Comparing data from before transfusion and baseline did not show statistically significant differences in any of cEPI or cADP measurements. cEPI means for the HBOC-201 group increased after transfusion compared to the true baseline (P = 0.01), before transfusion (P = 0.0004) and day 1 after transfusion (P = 0.002). cADP means for the HBOC-201 group were greater after transfusion compared to the true baseline (P = 0.05) and before transfusion (P = 0.005). In the PRBC group there were no significant difference in cEPI and cADP means between all of the time periods. Our study shows that HBOC-201 causes mild platelet dysfunction. Although there were significant changes after HBOC infusion and cEPI and cADP mean values were above the upper normal limit, they did not reach the non-closure time. Further controlled studies are needed to establish definitively the effects that HBOC-201 has on platelet function in patients.

Original languageEnglish (US)
Pages (from-to)140-147
Number of pages8
JournalAmerican Journal of Therapeutics
Volume17
Issue number2
DOIs
StatePublished - Mar 2010

Fingerprint

Multicenter Studies
Orthopedics
Blood Platelets
Erythrocytes
Research Ethics Committees
Blood Group Antigens
HBOC 201
Anesthesia

Keywords

  • HBOC-201
  • Hemoglobin-based oxygen carrier
  • Hemoglobin-glutamer 250 (bovine)
  • Hemopure
  • PFA-100
  • Platelet dysfunction

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Does HBOC-201 (hemopure) affect platelet function in orthopedic surgery : A single-site analysis from a multicenter study. / Jahr, Jonathan S.; Liu, Hong; Albert, Olga K.; Gull, Amy; Moallempour, Mojgan; Lim, Jennifer; Gosselin, Robert.

In: American Journal of Therapeutics, Vol. 17, No. 2, 03.2010, p. 140-147.

Research output: Contribution to journalArticle

Jahr, Jonathan S. ; Liu, Hong ; Albert, Olga K. ; Gull, Amy ; Moallempour, Mojgan ; Lim, Jennifer ; Gosselin, Robert. / Does HBOC-201 (hemopure) affect platelet function in orthopedic surgery : A single-site analysis from a multicenter study. In: American Journal of Therapeutics. 2010 ; Vol. 17, No. 2. pp. 140-147.
@article{d8ce7e8204324ec6a0fde93f009b0eb1,
title = "Does HBOC-201 (hemopure) affect platelet function in orthopedic surgery: A single-site analysis from a multicenter study",
abstract = "HBOC-201, Hemoglobin glutamer-250 (bovine), (Biopure Corp., Cambridge, MA) has been studied in an international, multicenter, pivotal Phase III trial. A subset analysis of use of blood products indicated that the HBOC-201 group required no more than the packed red blood cell (PRBC) group and was limited to less than 6{\%} in both treatment groups. In a subset analysis from one site, platelet function using PFA-100 was assessed before and after transfusion, and compared those receiving HBOC-201 versus PRBC. After initial IRB approval, patient consent for the Phase III trial and blood draws for PFA-100, an additional IRB exemption for retrospective chart review was obtained. cEPI and cADP means were compared at seven time periods: true baseline(before starting surgery and anesthesia), before transfusion, after transfusion, 1 day, 2 days, 3 to 9 days and 21 or more days after transfusion. Twenty-seven (HBOC: n = 12, PRBC: n = 15) subjects were studied. Comparing data from before transfusion and baseline did not show statistically significant differences in any of cEPI or cADP measurements. cEPI means for the HBOC-201 group increased after transfusion compared to the true baseline (P = 0.01), before transfusion (P = 0.0004) and day 1 after transfusion (P = 0.002). cADP means for the HBOC-201 group were greater after transfusion compared to the true baseline (P = 0.05) and before transfusion (P = 0.005). In the PRBC group there were no significant difference in cEPI and cADP means between all of the time periods. Our study shows that HBOC-201 causes mild platelet dysfunction. Although there were significant changes after HBOC infusion and cEPI and cADP mean values were above the upper normal limit, they did not reach the non-closure time. Further controlled studies are needed to establish definitively the effects that HBOC-201 has on platelet function in patients.",
keywords = "HBOC-201, Hemoglobin-based oxygen carrier, Hemoglobin-glutamer 250 (bovine), Hemopure, PFA-100, Platelet dysfunction",
author = "Jahr, {Jonathan S.} and Hong Liu and Albert, {Olga K.} and Amy Gull and Mojgan Moallempour and Jennifer Lim and Robert Gosselin",
year = "2010",
month = "3",
doi = "10.1097/MJT.0b013e3181a2b08d",
language = "English (US)",
volume = "17",
pages = "140--147",
journal = "American Journal of Therapeutics",
issn = "1075-2765",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Does HBOC-201 (hemopure) affect platelet function in orthopedic surgery

T2 - A single-site analysis from a multicenter study

AU - Jahr, Jonathan S.

AU - Liu, Hong

AU - Albert, Olga K.

AU - Gull, Amy

AU - Moallempour, Mojgan

AU - Lim, Jennifer

AU - Gosselin, Robert

PY - 2010/3

Y1 - 2010/3

N2 - HBOC-201, Hemoglobin glutamer-250 (bovine), (Biopure Corp., Cambridge, MA) has been studied in an international, multicenter, pivotal Phase III trial. A subset analysis of use of blood products indicated that the HBOC-201 group required no more than the packed red blood cell (PRBC) group and was limited to less than 6% in both treatment groups. In a subset analysis from one site, platelet function using PFA-100 was assessed before and after transfusion, and compared those receiving HBOC-201 versus PRBC. After initial IRB approval, patient consent for the Phase III trial and blood draws for PFA-100, an additional IRB exemption for retrospective chart review was obtained. cEPI and cADP means were compared at seven time periods: true baseline(before starting surgery and anesthesia), before transfusion, after transfusion, 1 day, 2 days, 3 to 9 days and 21 or more days after transfusion. Twenty-seven (HBOC: n = 12, PRBC: n = 15) subjects were studied. Comparing data from before transfusion and baseline did not show statistically significant differences in any of cEPI or cADP measurements. cEPI means for the HBOC-201 group increased after transfusion compared to the true baseline (P = 0.01), before transfusion (P = 0.0004) and day 1 after transfusion (P = 0.002). cADP means for the HBOC-201 group were greater after transfusion compared to the true baseline (P = 0.05) and before transfusion (P = 0.005). In the PRBC group there were no significant difference in cEPI and cADP means between all of the time periods. Our study shows that HBOC-201 causes mild platelet dysfunction. Although there were significant changes after HBOC infusion and cEPI and cADP mean values were above the upper normal limit, they did not reach the non-closure time. Further controlled studies are needed to establish definitively the effects that HBOC-201 has on platelet function in patients.

AB - HBOC-201, Hemoglobin glutamer-250 (bovine), (Biopure Corp., Cambridge, MA) has been studied in an international, multicenter, pivotal Phase III trial. A subset analysis of use of blood products indicated that the HBOC-201 group required no more than the packed red blood cell (PRBC) group and was limited to less than 6% in both treatment groups. In a subset analysis from one site, platelet function using PFA-100 was assessed before and after transfusion, and compared those receiving HBOC-201 versus PRBC. After initial IRB approval, patient consent for the Phase III trial and blood draws for PFA-100, an additional IRB exemption for retrospective chart review was obtained. cEPI and cADP means were compared at seven time periods: true baseline(before starting surgery and anesthesia), before transfusion, after transfusion, 1 day, 2 days, 3 to 9 days and 21 or more days after transfusion. Twenty-seven (HBOC: n = 12, PRBC: n = 15) subjects were studied. Comparing data from before transfusion and baseline did not show statistically significant differences in any of cEPI or cADP measurements. cEPI means for the HBOC-201 group increased after transfusion compared to the true baseline (P = 0.01), before transfusion (P = 0.0004) and day 1 after transfusion (P = 0.002). cADP means for the HBOC-201 group were greater after transfusion compared to the true baseline (P = 0.05) and before transfusion (P = 0.005). In the PRBC group there were no significant difference in cEPI and cADP means between all of the time periods. Our study shows that HBOC-201 causes mild platelet dysfunction. Although there were significant changes after HBOC infusion and cEPI and cADP mean values were above the upper normal limit, they did not reach the non-closure time. Further controlled studies are needed to establish definitively the effects that HBOC-201 has on platelet function in patients.

KW - HBOC-201

KW - Hemoglobin-based oxygen carrier

KW - Hemoglobin-glutamer 250 (bovine)

KW - Hemopure

KW - PFA-100

KW - Platelet dysfunction

UR - http://www.scopus.com/inward/record.url?scp=77949942370&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949942370&partnerID=8YFLogxK

U2 - 10.1097/MJT.0b013e3181a2b08d

DO - 10.1097/MJT.0b013e3181a2b08d

M3 - Article

C2 - 19417588

AN - SCOPUS:77949942370

VL - 17

SP - 140

EP - 147

JO - American Journal of Therapeutics

JF - American Journal of Therapeutics

SN - 1075-2765

IS - 2

ER -